JPS58186419A - Absorption of sulfur dioxide in solution - Google Patents

Absorption of sulfur dioxide in solution

Info

Publication number
JPS58186419A
JPS58186419A JP58061570A JP6157083A JPS58186419A JP S58186419 A JPS58186419 A JP S58186419A JP 58061570 A JP58061570 A JP 58061570A JP 6157083 A JP6157083 A JP 6157083A JP S58186419 A JPS58186419 A JP S58186419A
Authority
JP
Japan
Prior art keywords
solution
absorbent
absorption
sodium
sulfur dioxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP58061570A
Other languages
Japanese (ja)
Inventor
ドクタ−・フリ−ドリツヒ・ヴイルヘルム・キ−ネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JPS58186419A publication Critical patent/JPS58186419A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D53/00—Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols
    • B01D53/34—Chemical or biological purification of waste gases
    • B01D53/46—Removing components of defined structure
    • B01D53/48—Sulfur compounds
    • B01D53/50—Sulfur oxides
    • B01D53/501—Sulfur oxides by treating the gases with a solution or a suspension of an alkali or earth-alkali or ammonium compound
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B11/00—Oxides or oxyacids of halogens; Salts thereof
    • C01B11/08—Chlorous acid
    • C01B11/10—Chlorites
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B13/00—Oxygen; Ozone; Oxides or hydroxides in general
    • C01B13/02—Preparation of oxygen

Abstract

The invention provides a stabilized activated oxygen in matrix of chlorite ions and pharmaceutical compositions containing this stabilized activated oxygen. The stabilized activated oxygen is present in the form of a solution. The medication can be used for the treatment of skin diseases or wound healing disorders.

Description

【発明の詳細な説明】 本発明は、溶液中の二酸化硫黄を吸収する方法に関する
。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a method for absorbing sulfur dioxide in solution.

二酸化硫黄の吸収は煙道ガスの脱硫にとって非常に重要
である。たとえばドイツの新しい大型燃焼施設規定（Ｇ
ＩＦＩＯ）　Ｋよると石脚燃焼式火力発電所施設ではＳ
Ｏ，放出量が排煙１ｆｌｌ’当り４０Ω１ｖを超えては
ならないので、この施設の排煙は大部分脱硫せねばなら
ない。Sulfur dioxide absorption is very important for flue gas desulfurization. For example, Germany's new large-scale combustion facility regulations (G
IFIO) According to K, in the stone leg combustion type thermal power plant facility, S
O, the flue gas of this facility must be largely desulfurized, since the emissions must not exceed 40 ohms/fll' of flue gas.

周知の湿式排煙脱硫法はおもに洗浄器、吸収剤及び最終
生成物のタイプが種々異なる点で互いに相違している。Known wet flue gas desulfurization processes differ from one another primarily in the different types of scrubbers, absorbents and final products.

バー・ゲートベルレット（Ｈ６Ｇｕｔｂ＠ｒｌｅｔ　）
及びニス・シュタベルト（Ｓ、５ｔｉｐｐ・ｒｔ）カ雑
誌［７アウ・ゲー・Ｒ−発電所技術Ｊ　　（ＶＧＢＫｒ
ｉｆｔｗｅｒｋｓｔ＠ａｈｎｉｋ　）　、＠　６１巻第
１０号（１９８１年１０月）、８４９〜８５６頁におい
て、排煙脱硫装置の実際的経験について報告し１排煙か
ら洗い出した二酸化硫黄を消石灰を用いて七ツフウに変
換させ、こうして得たセツコラを工業的に継続処理する
ことを述べている。Bar Gate Belllet (H6Gutb@rlet)
and Niss Stabelt (S, 5tipp.rt) Ka Magazine [7 Au Ge R - Power Plant Technology J (VGBKr
iftwerkst@ahnik), Vol. 61, No. 10 (October 1981), pp. 849-856, reports on practical experience with flue gas desulfurization equipment. It describes the continuous industrial processing of the Setsukola obtained in this way.

しかしこの七ツコウは受入れの点ですでに困難がある。However, there are already difficulties in accepting this group.

本発明の課題は、吸収剤の＠数カを高め、またより有用
な生成物を生ずる新しい二酸化硫黄の吸収法を提供する
ことにある。It is an object of the present invention to provide a new method for absorbing sulfur dioxide which increases the number of absorbents and also results in more useful products.

この課題は本発明によって、亜塩素酸塩イオンから成る
母材に包接されたアルカリｐＨ価の安定化活性酸素水溶
液を吸収剤として用いることにより達成される。This object is achieved according to the invention by using as absorbent a stabilized aqueous solution of active oxygen with an alkaline pH number, which is included in a matrix consisting of chlorite ions.

本発明方法で使用する吸収剤は吸収力が高く１排煙の脱
硫度が本質的に高まる。本発明で使用する吸収剤け１方
で酸化作用を有しているため吸収した８０．を酸化させ
て硫酸塩とし、吸収平衡から不可逆的にそれを除去させ
、また他方でｐＨ価が烏いのでＳＯｌと塩基性化合愉と
の反応を促進させ反応生成物を作る。本発明方法の生成
物として１ｋｌｌナトリウム、特にグラウパー塩が得ら
れ、これはグラウパー塩電池としてリサイクリング操作
の意味でエネルギー獲得又は貯蔵のため利用することが
できる。The absorbent used in the process of the invention has a high absorption capacity and essentially increases the degree of desulfurization per flue gas. 80. The absorbent used in the present invention has an oxidizing effect and is therefore absorbed. is oxidized to sulfate, irreversibly removing it from the absorption equilibrium, and on the other hand, the high pH value promotes the reaction of SOI with basic compounds to form reaction products. The product of the process according to the invention is 1 kiloliter of sodium, in particular Grauper's salt, which can be used as a Grauper's salt battery for energy harvesting or storage in the sense of recycling operations.

本発明で使用する吸収剤は亜塩素酸塩イオンから成る母
材に包接された活性酸素から成り、一般式 ％式％（） で表わすことができる（式中ｎはα１〜α２５の値を意
味する）。吸収剤として使用する水溶液はアルカリｐＨ
価、好ましくは１１．０〜１五５のｐＨ価である。The absorbent used in the present invention consists of active oxygen clathrated in a matrix consisting of chlorite ions, and can be expressed by the general formula % (in which n is the value of α1 to α25). means). The aqueous solution used as an absorbent has an alkaline pH.
The pH value is preferably 11.0 to 155.

本発明方法において室温又は昇温下、前記溶液にＳＯ，
を入れると下記の反応が起きる。In the method of the present invention, SO,
When you add , the following reaction occurs.

ｉ９０．−１−４０Ｈ−−＋　ｓｏ、ｘ−＋２＠−）２
Ｈ，Ｏ（２Ｘ）０１０、−−１−４・＋２Ｈ３０→Ｏ１
″″＋４０Ｈ−２８０、＋　４０Ｈ−＋　０１０．−→
２　ＳＯ，”−＋　Ｏｌ−＋２　Ｈ，０これらの反応、
は、吸収割管かなり希釈した場合でも起き、ラマン分光
法で検証することができる。つまり、本発明方法では吸
収溶液の高いｐＨ価に鳥づいてＳＯ，の吸収が起きるだ
けでなくＳＯ，の硫酸塩への酸化も起きる。本発明で使
用するｐＨ価１ｔｏ〜１４に５の吸収１ｌｌＩ液１ｊ当
りの吸収力は、酸化によって約２００〜ｚｚｏｙｓｏ、
、吸収によって約４００ｊｌ１９０．である。i90. -1-40H--+ so, x-+2@-)2
H,O(2X)010,--1-4・+2H30→O1
″″+40H-280, +40H-+010. −→
2 SO,”-+ Ol-+2 H,0 These reactions,
This occurs even when the absorption split tube is significantly diluted and can be verified by Raman spectroscopy. That is, in the method of the present invention, not only the absorption of SO, due to the high pH value of the absorption solution, but also the oxidation of SO to sulfate occurs. The absorption power per 1 j of the absorption liquid with a pH value of 1 to 14 to 5 used in the present invention increases by oxidation to about 200 to
, about 400jl190. by absorption. It is.

亜塩素酸塩イオンから成る母材に包接された安定化活性
酸素の水溶液から成る本発明で使用する吸収剤は、亜塩
素酸すＦリウム等の亜塩素酸塩を水溶液のなかで次亜塩
素酸ナトリウム等の次亜塩素酸塩と反応させることによ
り製造することができる。この反応は亜塩素酸塩１に対
し次亜塩素酸塩ａ２〜ｃＬ５、好ましくは（１２５のモ
ル比において起きる。この溶媒において１時間以内に析
出物が変化することはない。Ｍ塩素酸ナトリウムと次亜
塩素酸ナトリウムとのこのアルカリ溶液Ｋｒクロリル硫
酸」を滴加して４４〜表８ＯｐＨ価にすると、二酸化塩
素と電荷移動錯体（０１，０，）−が得られ、次に過酸
化炭酸塩又は過酸化硼酸塩、たとえば過硼酸ナトリウム
又は過炭酸ナトリウムを添加しそして引き続き過酸化ナ
トリウムを添加すると前記錯体から二酸化塩素が追い出
され、活性酸素を包接して含んだ亜塩素酸塩イオンの母
材が得られる。The absorbent used in the present invention, which is composed of an aqueous solution of stabilized active oxygen clathrated in a matrix consisting of chlorite ions, is composed of an aqueous solution of stabilized active oxygen clathrated in a matrix consisting of chlorite ions. It can be produced by reacting with a hypochlorite such as sodium chlorate. The reaction takes place in a molar ratio of 1 to 1 of chlorite to 1 of hypochlorite, preferably (125).The precipitate does not change within 1 hour in this solvent. Addition of this alkaline solution Krchloryl sulfate with sodium hypochlorite dropwise to a pH value of 44 to Table 8 gives chlorine dioxide and the charge transfer complex (01,0,)-, followed by peroxide carbonate. or the addition of a perborate salt, such as sodium perborate or sodium percarbonate, followed by the addition of sodium peroxide drives the chlorine dioxide from the complex, forming a matrix of chlorite ions containing active oxygen in clathrate form. is obtained.

上述の一連の反応は次のように説明することができる。The series of reactions described above can be explained as follows.

２０１０、−＋００１″″＋２Ｈ→２０１０．−）　０
１−　＋Ｈ，Ｏ（１１０１０、−１−０１０ｔ″″　→
　　（０１，０，）　−（２）亜塩素酸塩は装入量の半
分が式（１）により酸化趨元過程で鹸化して０１０．と
なる。得られた二酸化塩素と酸化しなかった残り半分の
亜塩素酸塩とから式（２）により濃褐色の電荷移動錯体
が得られる。2010, -+001″″+2H→2010. -) 0
1- +H,O(11010,-1-010t″″ →
(01,0,) - (2) Half of the charged amount of chlorite is saponified in the oxidation process according to formula (1), and 010. becomes. A dark brown charge transfer complex is obtained from the obtained chlorine dioxide and the remaining half of the unoxidized chlorite according to formula (2).

６０〜９０分後、収率が最高となる。次に、将来の用途
に応じて、微量のＮＫ＊００．　Ｘ　Ｈ，Ｏ，又はＮ　
ａ　Ｂ　Ｏ＠　Ｘ　Ｈ１０＊　Ｘ　３１ｆ−ｔ−溶液に
混ぜる。溶液は黄色に変色する。溶解した二酸化塩素は
１部が過酸化物によって酸素を激しく発生しつつ還元さ
れて再び亜塩素酸塩となる。１５分後、微量のＮ＊２０
Ｂを溶液に加える。残留０１０．が還元されて０１０ｍ
−になるので溶液はいまや完全に無色となる。最低４週
間、通常６週間以上というきわめてゆっくりした反応に
おいて、活性酸素を含有した亜塩素酸塩イオンの母材が
生成し、同時にヒドロオキシルイオンが生成する。この
反応を早めることはできない。ｐｉｉ価は１五８にまで
高まる。各種の実験から、溶液上のガス体積が酸素含量
に影響することがわかった。最も好ましい比は溶液２７
５に対しガス体積１／６である。The yield is highest after 60-90 minutes. Next, depending on the future application, a trace amount of NK*00. X H, O, or N
a B O@X H10* X 31ft- Mix with the solution. The solution turns yellow. A portion of the dissolved chlorine dioxide is reduced by peroxide while vigorously generating oxygen, and becomes chlorite again. After 15 minutes, a trace amount of N*20
Add B to the solution. Residue 010. has been reduced to 010m
-, so the solution is now completely colorless. In a very slow reaction of at least 4 weeks, but usually more than 6 weeks, a matrix of chlorite ions containing active oxygen is formed, and at the same time hydroxyl ions are formed. This reaction cannot be accelerated. The pii value increases to 158. Various experiments have shown that the gas volume above the solution affects the oxygen content. The most preferred ratio is solution 27
5, the gas volume is 1/6.

式（１）により得られる二除化塩素量から見て、亜塩素
酸塩と酸素との化学量論比は４：１と予想すべきであろ
う。場合によっては過給化水素の不均化反応により発生
する酸素がこれに加わる。つまり前記の比より酸素がさ
らに増すはずであろう。だが酸素定量の結果、そのよう
に高い酸素濃度は不可能であり、また１方で０１０．”
−母材において酸素の溶解度が限られ、他方で任意に高
い酸素分圧は維持できないばかりか希望する過酸化物の
還元を阻止させないためにも望ましくないものであるか
ら、過剰酸素は漏れ出ることがわかった。In view of the amount of dichloride obtained by formula (1), the stoichiometric ratio of chlorite to oxygen should be expected to be 4:1. In some cases, oxygen generated by the disproportionation reaction of supercharged hydrogen is added to this. In other words, the amount of oxygen should increase further than the above ratio. However, as a result of oxygen determination, such a high oxygen concentration is impossible, and on the other hand, 0.10. ”
- Excess oxygen cannot escape, since the solubility of oxygen in the matrix is limited and, on the other hand, arbitrarily high oxygen partial pressures are not only unsustainable but also undesirable because they do not prevent the desired peroxide reduction. I understand.

０１０、−と下記の平衡状態にある０１０−イオンの存
在は接穂効果（ムｎｉｍｐｆ＠ｆｆ＠ｋｔ　）を呼び起
こす・ ００１０ｘ−＋２ＨＯ８ＯＢＨＨ０１０１＋２８０４ｆ
＋Ｈ１０（３）そしてＳ該効果が反応を二酸化塩素の方
向に向ける。The presence of the 010- ion in the following equilibrium state with 010,- evokes the scion effect (mu nimpf@ff@kt) 0010x-+2HO8OBHH0101+2804f
+H10(3) and the S effect directs the reaction towards chlorine dioxide.

０１０、　　＋〇ＩＧ、−→２０１０．　　　　　　　
（４）これにより塩素除塩の発生が抑えられる。010, +〇IG, -→2010.
(4) This suppresses the occurrence of chlorine removal.

こうして得られた吸収剤はナトリウムイオンも含んでい
るので１＠収剤にＳＯ，を入れて前述の反応、すなわち
硫酸塩への酸化の後、Ｓｏ、２モルに対し硫酸ナトリウ
ム２モル及び塩化ナトリウムイオンが生成する。この２
つの塩は通常の分層操作で分離させることができる。Since the absorbent thus obtained also contains sodium ions, SO is added to the absorbent and after the above reaction, that is, oxidation to sulfate, 2 moles of So, 2 moles of sodium sulfate, and 2 moles of sodium chloride are added to the absorbent. Ions are generated. This 2
The two salts can be separated by conventional layer separation operations.

得られた硫酸ナトリウムはグララバー塩の形でその場で
、すなわち大振燃焼設備の敷地内、又は他のＮｉ地で、
エネルギー源として使用することができる。周知の如く
、５Ｌ５Ｂ℃以下の温度では水溶液から硫酸ナトリウム
が無色単斜晶の形の１０水化物（グララバー塩）として
晶つバー塩は熱を消費しつつ水に溶けるが（＠熱）、無
水塩は熱を発生しつつ溶ける（発熱）。吸収剤に導入す
るさい排煙温度を選択することにより吸収剤の温度、従
って発生する硫酸すＦリウムの結晶形状を制御すること
か、できる。The obtained sodium sulfate is in the form of Glaraber salt in situ, i.e. on the premises of the Daishi combustion facility or at other Ni sites.
Can be used as an energy source. As is well known, at temperatures below 5L5B°C, sodium sulfate crystallizes from an aqueous solution as a colorless monoclinic decahydrate (Glarbar salt). Barr salt dissolves in water while consuming heat (@heat), but anhydrous Salt melts while generating heat (exothermic). By selecting the flue gas temperature during introduction into the absorbent, it is possible to control the temperature of the absorbent and, therefore, the crystal shape of the generated F sulfate.

本発明を下記実施例により詳述する。The present invention will be explained in detail with reference to the following examples.

実施例 Ａ、吸収剤の製造 密閉容器のなかで蒸留水！ｊＫＭ塩素酸ナトリウム１０
４４．＠（１モル）を溶かした溶液と、次亜塩素酸ナト
リウム１２１モルに相当すル活性塩素含量１５％の次亜
塩素酸す）　ＩＪウム溶液９２．８ｍとを混ぜた。ｐＨ
価１α４のこの溶液を慎重に攪拌しつつ、触媒として加
えるＫＯＩＯ。Example A, production of absorbent Distilled water in a closed container! jKM sodium chlorate 10
44. A solution containing 1 mol of sodium hypochlorite was mixed with 92.8 ml of a hypochlorous acid solution with an active chlorine content of 15%, which corresponds to 121 mol of sodium hypochlorite. pH
Add KOIO as a catalyst while carefully stirring this solution with a value of 1α4.

４８１１１ｇ（５＆４Ｘ１０　　モル）に相当するクロ
リル硫酸を１滴ずつ加えて溶液のｐＨ価を４４〜＆８に
した。反応時間９０分後、溶液に過硼酸ナトリウム（Ｍ
ａＢＯ，Ｘ　Ｈ，Ｏ，Ｘ　ＡＨ，Ｏ）　６９　（（１０
ｎ　９モル）を慎重に加え、次に強力に攪拌して二酸化
塩素を追い出した。１墨分間強力に反応させた後、得ら
れた反応混合物に過酸化ナトリウム（Ｍａｔ’ｓ）　１
２　ｆｉ　（（１１５４モル）を加えた。そのさい生じ
る発熱反応を連続攪拌によって阻止した。約６遍間後、
活性Ｏ！と０１０．−との錯体の水溶液の形の生成物を
、沈殿した硼酸ナトリウムからＰｆＭした。Chloryl sulfuric acid corresponding to 48111 g (5&4×10 mol) was added dropwise to bring the pH value of the solution to 44-&8. After 90 minutes of reaction time, sodium perborate (M
aBO,X H,O,X AH,O) 69 ((10
n 9 mol) was added carefully and then stirred vigorously to drive off the chlorine dioxide. After reacting vigorously for 1 minute, add 1 portion of sodium peroxide (Mat's) to the resulting reaction mixture.
2 fi ((1154 mol)) was added. The resulting exothermic reaction was prevented by continuous stirring. After about 6 hours,
Active O! and 010. - The product in the form of an aqueous solution of the complex with PfM was obtained from the precipitated sodium borate.

得られた溶液は１４５〜１五８のｐＨ価であるがアルカ
リ特性を有しておらず、アルコールと混合可能な融点−
５℃の透明な液体であり、ラマンスペクトルの帯域は主
に４ｏｌａ０２ｃｓ　　（Ｍ塩素厳塩）及び１．５４２
　Ｃａｌ　　（活性酸素）であった。The resulting solution has a pH value of 145-158 but has no alkaline properties and has a melting point that is miscible with alcohol.
It is a transparent liquid at 5℃, and the Raman spectrum bands are mainly 4ola02cs (M chlorine severe salt) and 1.542
Cal (active oxygen).

後に挙げた帯域を測定するため、０．のラマンスペクト
ルの帯域はＪ（ｏＨ，）の帯域と一部重なるので、Ｄ宜
０を用い前述の手ｊｉｂ従って混合を行った。こうして
得られた濃縮物において、低い波数では同位体効果のゆ
えＪ（ＯＤ、）が現われるので、１，５４２ｃｍ　　附
近に０．帯域をはっきり確定することができた。亜塩素
酸塩母材内の活性酸素（Ｄ　Ｏ−ＯｒＭＪＩＩｉｌ　１
２　Ｓ　ｐ鳳ト算Ｊｆ５　’ｊＥ　レタｏ　従ッてこの
結合は非活性酸素（１２Ｇ）ｍ）よりかなり長くなって
いた。In order to measure the bands mentioned later, 0. Since the band of the Raman spectrum partially overlaps with the band of J(oH,), mixing was performed using DIO according to the above-mentioned method. In the concentrate obtained in this way, J (OD, ) appears at low wavenumbers due to isotopic effects, so 0. I was able to clearly determine the range. Active oxygen in chlorite matrix (DO-OrMJIIil 1
2 S p Otori calculation Jf5 'jE Reta o Therefore, this bond was considerably longer than non-active oxygen (12G) m).

高圧液体クロマトグラフィーにより、１シロ鰺の場合吸
収ピークのＲＴ特性値は１１４であり、過酸化物、亜塩
素酸塩、次亜塩素酸塩及び塩素酸塩とはっきり相違して
いる。High-pressure liquid chromatography revealed that the RT characteristic value of the absorption peak for white mackerel was 114, which was clearly different from peroxide, chlorite, hypochlorite, and chlorate.

Ｂ、　　Ｓｏ、の吸収 項目ムで得られた液体１００１１ｇを水で薄めて１ｔ４
のｐＨ価にし、吸収剤として吸収塔に入れた。純正二酸
化硫黄をボンベから取り出し加熱装置に通してｓＯ℃ｒ
ｃ加熱した。次に８０．　ｉ　Ｓ　０℃の温度で吸収塔
に通した０反応をう！ンスペクトル分光法で検証し、Ｓ
Ｏ，がスムーズに硫酸塩に鹸化することをｉｌＭした。Dilute 10011g of the liquid obtained in the absorption item B, So, with water to make 1t4
The pH value was adjusted to , and it was put into an absorption tower as an absorbent. Take out pure sulfur dioxide from the cylinder and pass it through a heating device to sO℃r.
c Heated. Next 80. i S 0 reaction passed through an absorption tower at a temperature of 0°C! Verified by spectral spectroscopy, S
It was shown that O, smoothly saponified to sulfate.

得られた溶液から、５２．５８℃以上の温度においてｋ
ｍナトリウムの１部が無水塩として晶出し、ｓ２．ｓａ
°Ｃ以下の温度において残りの硫酸ナトリウムがグララ
バー塩として晶出した。From the resulting solution, k at a temperature of 52.58°C or higher
A portion of m sodium crystallizes out as an anhydrous salt, s2. sa
At temperatures below °C, the remaining sodium sulfate crystallized out as Glaraber salt.

本発明の実施の態様は次の通りである。The embodiments of the present invention are as follows.

１、　グララバー塩は発電所の冷却に使用されることを
特徴とする特許請求の範囲第２項に記載の方法。1. The method according to claim 2, characterized in that the Glaraber salt is used for cooling a power plant.

２　グララバー塩は太陽熱集熱器による加熱によってテ
ナルダイシに転換されることを特徴とする特許請求の範
囲第２＠記載の方法。2. The method according to claim 2, characterized in that Glaraber salt is converted to tenardic acid by heating with a solar collector.

五吸収剤として用いる溶液がナトリウムイオンも含み、
生成物としてテナルダイトが生じ、該テナルダイトはエ
ネルギー生産のために使用されることを特徴とする特許
請求の範囲第１項に記載の方法。The solution used as an absorbent also contains sodium ions,
2. Process according to claim 1, characterized in that the product is thenardite, which thenardite is used for energy production.

４　テナルダイトはエネルギー生産のために使用される
ことを特徴とする実施の態様第２項に記載の方法。4. The method according to embodiment 2, wherein the thenardite is used for energy production.

特許出願人　　　ドクター　フリードリツヒ外２４！１Patent applicant: Dr. Friedrich et al. 24!1

Claims (1)

【特許請求の範囲】 １、　溶液中の二酸化硫黄を吸収する方法において、Ｍ
＃１禦酸塩酸塩イオン成る母材に包接されたアルカリｐ
Ｈ価の安定化活性酸素水溶液を吸収剤として用いること
１−＊徴とする方法。 ２　該吸収剤として用いる溶液がナトリウムイオンも含
み、生成物として硫酸ナトリウム、特にグララバー塩が
生じることを特徴とする特許−求の範囲第１項に記載の
方法。 五　該二酸化硫黄諒として煙道ガスを用いることを特徴
とする特許請求の範Ｈ＄１項又は第２項に記載の方法。 ４・該吸収剤として用いる溶液のｐｐｍが、１１．０な
いし１４．５、好ましくは１ｔＯないし１五５であるこ
とを特徴とする特許請求の範囲！＠１項ないし第６項の
いずれか１項に記載の方法。[Claims] 1. In a method for absorbing sulfur dioxide in a solution, M
#1 Alkali p clathrated in a matrix consisting of chloride salt ions
A method characterized by using a stabilized active oxygen aqueous solution with an H value as an absorbent. 2. Process according to claim 1, characterized in that the solution used as absorbent also contains sodium ions and that sodium sulfate, in particular Glaraber salt, is produced as a product. 5. The method according to claim 1 or 2, characterized in that flue gas is used as the sulfur dioxide gas. 4. Claims characterized in that the ppm of the solution used as the absorbent is 11.0 to 14.5, preferably 1 tO to 155! @The method described in any one of Items 1 to 6.
JP58061570A 1982-04-10 1983-04-09 Absorption of sulfur dioxide in solution Pending JPS58186419A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE32133898 1982-04-10
DE19823213389 DE3213389A1 (en) 1982-04-10 1982-04-10 STABILIZED ACTIVATED OXYGEN AND MEDICINAL PRODUCTS CONTAINING THIS STABILIZED ACTIVATED OXYGEN

Publications (1)

Publication Number Publication Date
JPS58186419A true JPS58186419A (en) 1983-10-31

Family

ID=6160693

Family Applications (2)

Application Number Title Priority Date Filing Date
JP58061569A Expired - Lifetime JPH0641362B2 (en) 1982-04-10 1983-04-09 Stabilized active oxygen
JP58061570A Pending JPS58186419A (en) 1982-04-10 1983-04-09 Absorption of sulfur dioxide in solution

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP58061569A Expired - Lifetime JPH0641362B2 (en) 1982-04-10 1983-04-09 Stabilized active oxygen

Country Status (5)

Country Link
US (1) US4507285A (en)
EP (2) EP0091650B1 (en)
JP (2) JPH0641362B2 (en)
AT (2) ATE21046T1 (en)
DE (3) DE3213389A1 (en)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185161A (en) * 1984-03-21 1993-02-09 Alcide Corporation Disinfection method and composition therefor
US4986990A (en) * 1984-03-21 1991-01-22 Alcide Corporation Disinfection method and composition therefor
DE3515749A1 (en) * 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg USE OF A STABILIZED CHLORITE MATRIX SOLUTION IN INFECTIOUS CONDITIONS
DE3515748A1 (en) * 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg USE OF ISOTON CHLORITE MATRIX SOLUTION IN TUMOR TREATMENT
DE3515745A1 (en) * 1985-05-02 1986-11-06 Oxo Chemie GmbH, 6900 Heidelberg AQUEOUS CHLORITE MATRIX SOLUTION
DE3600931A1 (en) * 1986-01-15 1987-07-16 Oxo Chemie Gmbh Formulation of chlorite matrices in solution
DE3625867C2 (en) * 1986-07-31 1995-10-19 Elstner Erich F Prof Dr Use of tetrachloro decahydride in ophthalmology
JPS63201129A (en) * 1987-02-17 1988-08-19 Akira Yamabe Remedy and preventive for aquarium fish
US4891216A (en) * 1987-04-14 1990-01-02 Alcide Corporation Disinfecting compositions and methods therefor
US4851222A (en) * 1988-01-27 1989-07-25 Oxo Chemie Gmbh Method of promoting regeneration of bone marrow
DE4208828A1 (en) * 1992-03-19 1993-09-23 Oxo Chemie Gmbh USE OF A CHEMICALLY STABILIZED CHLORITE MATRIX FOR THE PRODUCTION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF HIV INFECTIONS
US5252343A (en) * 1992-03-20 1993-10-12 Alcide Corporation Method and composition for prevention and treatment of bacterial infections
US5830511A (en) * 1992-06-25 1998-11-03 Bioxy Inc. Therapeutic, production and immunostimulatory uses of biocidal compositions
US6099855A (en) * 1992-06-25 2000-08-08 Bioxy, Inc. Therapeutic, production and immunostimulatory uses of biocidal compositions
US6004587A (en) * 1992-06-25 1999-12-21 Bioxy Inc. Therapeutic, production and immunostimulatory uses of biocidal compositions
WO1995027472A1 (en) * 1994-04-07 1995-10-19 Richter Jon L Oral rinse and method of treating halitosis
GB9420201D0 (en) * 1994-10-06 1994-11-23 Green Bruce P Cold sterilant solution
US6007772A (en) * 1994-10-06 1999-12-28 Green; Bruce Philip Cold sterilant solution
US5885974A (en) * 1994-12-06 1999-03-23 Michael M. Danielov Therapeutic methods utilizing naturally derived bio-active complexes and delivery systems therefor
US5578022A (en) * 1995-04-12 1996-11-26 Scherson; Daniel A. Oxygen producing bandage and method
US5792090A (en) * 1995-06-15 1998-08-11 Ladin; Daniel Oxygen generating wound dressing
US5733884A (en) * 1995-11-07 1998-03-31 Nestec Ltd. Enteral formulation designed for optimized wound healing
US5855922A (en) * 1995-12-07 1999-01-05 Bio-Cide International, Inc. Antiseptic composition and process for prophylaxis and therapeutic treatment of dermal disorders
US5877222A (en) * 1996-07-19 1999-03-02 The Regents Of The University Of California Method for treating aids-associated dementia
US5993864A (en) * 1997-07-11 1999-11-30 Kross; Robert D. Chlorine dioxide chelate compositions and method of use
US5921251A (en) * 1997-08-07 1999-07-13 Ceramatec, Inc. Brush that delivers beneficial agents
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
US7654728B2 (en) * 1997-10-24 2010-02-02 Revalesio Corporation System and method for therapeutic application of dissolved oxygen
WO2000048940A1 (en) * 1999-02-19 2000-08-24 Stahl Kurt Wilhelm Peroxochloric acid, derivatives and anions, salts thereof, method for producing them and use of the same
AU2003247351A1 (en) 2002-04-25 2003-11-10 William O. Kling Anti-acne compositions and methods of use
GB2395906B (en) 2002-12-06 2006-06-14 Johnson & Johnson Medical Ltd Wound dressings containing an enzyme therapeutic agent
US20050118115A1 (en) * 2003-10-24 2005-06-02 Fontenot Mark G. Accelerated tooth whitening method, composition and kit
EP1687238B1 (en) 2003-11-21 2009-12-09 CytoTools AG Reactive chlorine compounds, the derivatives, anions, and salts thereof, method for the production thereof, and use thereof
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
US20050218103A1 (en) * 2004-04-01 2005-10-06 Barker Keith J Preform assembly, container assembly, and method of manufacture
US7704522B2 (en) * 2004-09-08 2010-04-27 Clyde Morgan Topical medicament
EP1799276B1 (en) * 2004-10-07 2017-05-03 Ngen Pharmaceuticals N.V. Composition for treating wounds and burns
US20080274206A1 (en) * 2004-10-07 2008-11-06 Ngen Pharmaceuticals N.V. Stabilised Oxygen Releasing Composition
CN100436308C (en) * 2004-12-08 2008-11-26 龙膺厚 Long-effective instant aqueous chlorine solution
DE102005006462A1 (en) * 2005-02-12 2006-09-07 Templa Tech Gmbh Agent for the treatment of infections
JP5371443B2 (en) * 2005-12-22 2013-12-18 ニューラルタス ファーマシューティカルズ，インコーポレイテッド Chlorite formulations and methods and uses of this preparation
CN100522181C (en) * 2006-06-30 2009-08-05 尚道坊科技发展（北京）有限公司 Anoxia and fatigue-resisting health-care oxygen, its preparation and use as health-care product
US8784898B2 (en) 2006-10-25 2014-07-22 Revalesio Corporation Methods of wound care and treatment
CA2667614A1 (en) * 2006-10-25 2008-09-25 Revalesio Corporation Method of wound care and treatment
US8597689B2 (en) 2006-10-25 2013-12-03 Revalesio Corporation Methods of wound care and treatment
US8784897B2 (en) * 2006-10-25 2014-07-22 Revalesio Corporation Methods of therapeutic treatment of eyes
US8609148B2 (en) * 2006-10-25 2013-12-17 Revalesio Corporation Methods of therapeutic treatment of eyes
WO2008052143A2 (en) 2006-10-25 2008-05-02 Revalesio Corporation Mixing device and output fluids of same
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
EP2155235B1 (en) * 2007-04-09 2016-04-06 Wake Forest University Health Sciences Oxygen-generating compositions for enhancing cell and tissue survival in vivo
CA2689075A1 (en) 2007-06-01 2008-12-04 Dimethaid Ag Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis
US7901388B2 (en) 2007-07-13 2011-03-08 Bacoustics, Llc Method of treating wounds by creating a therapeutic solution with ultrasonic waves
US7896854B2 (en) 2007-07-13 2011-03-01 Bacoustics, Llc Method of treating wounds by creating a therapeutic solution with ultrasonic waves
US20100310609A1 (en) * 2007-10-25 2010-12-09 Revalesio Corporation Compositions and methods for treatment of neurodegenerative diseases
US20100303917A1 (en) * 2007-10-25 2010-12-02 Revalesio Corporation Compositions and methods for treating cystic fibrosis
US9745567B2 (en) * 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US20100303918A1 (en) * 2007-10-25 2010-12-02 Revalesio Corporation Compositions and methods for treating asthma and other lung disorders
US20100008997A1 (en) * 2007-10-25 2010-01-14 Revalesio Corporation Compositions and methods for treating asthma and other lung disorders
US20100004189A1 (en) * 2007-10-25 2010-01-07 Revalesio Corporation Compositions and methods for treating cystic fibrosis
US20100009008A1 (en) * 2007-10-25 2010-01-14 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
US20100310665A1 (en) * 2007-10-25 2010-12-09 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
US20100015235A1 (en) * 2008-04-28 2010-01-21 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US20100029764A1 (en) * 2007-10-25 2010-02-04 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US20100303871A1 (en) * 2007-10-25 2010-12-02 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US20120114702A1 (en) * 2007-10-25 2012-05-10 Revalesio Corporation Compositions and methods for treating asthma and other lung disorders
US20090227018A1 (en) * 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US20090263495A1 (en) * 2007-10-25 2009-10-22 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
US9523090B2 (en) * 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US10125359B2 (en) * 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US7950594B2 (en) * 2008-02-11 2011-05-31 Bacoustics, Llc Mechanical and ultrasound atomization and mixing system
CN103919804A (en) * 2008-05-01 2014-07-16 利发利希奥公司 Compositions And Methods For Treating Digestive Disorders
JP2010077004A (en) * 2008-09-29 2010-04-08 Taikoo:Kk Method for stabilizing chlorite solution, stabilized chlorite solution, method for generating chlorine dioxide and method for removing the same
US20100098687A1 (en) * 2008-10-22 2010-04-22 Revalesio Corporation Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions
MX2011009950A (en) 2009-03-23 2012-02-28 Kross Link Lab Inc Method for suppressing or preventing fibrous adhesion formation using a multicomponent aqueous oxychlorine composition prepared on-site.
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
EA201290041A1 (en) 2009-08-06 2012-07-30 Ньюралтус Фармасьютикалс, Инк. TREATMENT OF DISORDERS ASSOCIATED WITH MACROPHAGES
EP2566460A4 (en) 2010-05-07 2015-12-23 Revalesio Corp Compositions and methods for enhancing physiological performance and recovery time
MX2013001636A (en) 2010-08-12 2013-05-01 Revalesio Corp Compositions and methods for treatment of taupathy
CA2807723A1 (en) * 2010-08-13 2012-02-16 Servet Buyuktimkin Foamable compositions of stabilized chlorite
CN103796515B (en) 2011-03-18 2017-05-03 瑞尔姆治疗股份有限公司 Stabilized hypohalous acid solutions
US11452778B2 (en) 2011-03-18 2022-09-27 Urgo Us, Inc. Stabilized hypohalous acid solutions
US9381214B2 (en) 2011-03-18 2016-07-05 Puricore, Inc. Methods for treating skin irritation
JP2014511879A (en) * 2011-04-13 2014-05-19 レバレジオ コーポレイション Compositions and methods for inhibiting and / or modulating effector T cells involved in inflammatory neurodegenerative diseases
WO2013093891A1 (en) 2011-12-22 2013-06-27 Nuvo Research Gmbh Liposomal chlorite or chlorate compositions
WO2014037927A1 (en) * 2012-09-10 2014-03-13 Nuvo Research Gmbh Chlorate compositions and use of chlorate for treating radiation exposure
JP6339985B2 (en) * 2015-08-19 2018-06-06 内外化学製品株式会社 Method for reducing chlorine dioxide concentration in water and water treatment agent for reducing chlorine dioxide concentration in water
JP2017209679A (en) * 2017-09-11 2017-11-30 内外化学製品株式会社 Method for reducing chlorine dioxide concentration underwater, and water treatment agent for reducing chlorine dioxide concentration underwater
KR102607681B1 (en) 2020-09-16 2023-11-28 충남대학교산학협력단 Composition for preventing, improving or treating of epileptic seizure or convulsion containing water of activated stabilized oxygen(ASO)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4073873A (en) * 1976-03-29 1978-02-14 The Dow Chemical Company Catalytic decomposition of hypochlorite
DE2615339A1 (en) * 1976-04-08 1977-10-13 Agfa Gevaert Ag Sulphurous effluents purification - by treating with an alkaline chlorite soln.
US4297333A (en) * 1980-07-07 1981-10-27 Ppg Industries, Inc. Method of decomposing hypochlorite ion in a basic solution
US4296103A (en) * 1980-08-08 1981-10-20 Felipe Laso Stabilized solution of chlorine oxides
US4343715A (en) * 1980-10-10 1982-08-10 Duke University Immobilized hemoglobin, and processes for extracting oxygen from fluids using the same

Also Published As

Publication number Publication date
DE3213389A1 (en) 1983-10-20
EP0093875B1 (en) 1987-11-04
US4507285A (en) 1985-03-26
JPH0641362B2 (en) 1994-06-01
EP0091650B1 (en) 1986-07-30
DE3364858D1 (en) 1986-09-04
EP0091650A2 (en) 1983-10-19
ATE30575T1 (en) 1987-11-15
JPS58185404A (en) 1983-10-29
EP0093875A1 (en) 1983-11-16
EP0091650A3 (en) 1983-11-16
ATE21046T1 (en) 1986-08-15
DE3374300D1 (en) 1987-12-10

Similar Documents

Publication Publication Date Title
JPS58186419A (en) Absorption of sulfur dioxide in solution
JPH0656413A (en) Production of hexafluorophosphate salt
Kharasch et al. Derivatives of Sulfenic Acids. XVII. The Hydrolysis of 2, 4-Dinitrobenzenesulfenyl Chloride
JPS61205602A (en) Manufacture of chlorine dioxide
Baxter et al. CXCVI.—N-halogen derivatives of the p-halogen-substituted benzenesulphonamides
US3673245A (en) Treatment of off-gases from nitric acid oxidation of anolone
US1978431A (en) Process of producing nitrites
US4867956A (en) Active oxygen-rich compound and preparative method
US3690824A (en) Desulfurization of flue gas
CA2387958A1 (en) Method of preparing valproic acid compounds
JPS62108730A (en) Synthesizing method for hexafluoroantimonic acid and hexafluoroantimonate
SU598895A1 (en) Method of obtaining formylpyrazine
GB834594A (en) Preparation of perchloryl fluoride
Kolcu et al. Thermal properties of sodium—light-lanthanoid double sulfate monohydrates
US225730A (en) stillman
Frankland V. Researches on organo-metallic bodies.—Third Memoir. On a new series of organic acids containing nitrogen
GB1061555A (en) Improvements in or relating to the production of potassium monopersulphate
JPS5835168A (en) Preparation of cystamine
CN115125046A (en) Sulfur-free odorizing agent for natural gas
US226632A (en) Thomas b
CN1041402C (en) Controlling method used in the synthesizing course of directly making lithium bromide
Schwind Barium: A Bibliography of Unclassified Literature
JPS6065703A (en) Production of high-purity chlorine dioxide
JPH0577609B2 (en)
May CCVII.—Aromatic antimony compounds. Part I. The oxidation and nitration of triphenylstibine